Menu Search
Equities

Kura Oncology Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
KUR:DUS

Kura Oncology Inc

Actions
  • Price (EUR)6.42
  • Today's Change-0.004 / -0.06%
  • Shares traded650.00
  • 1 Year change-18.75%
  • Beta0.2393
Data delayed at least 15 minutes, as of Feb 12 2026 18:31 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a FTI, is being evaluated in a Phase I dose-escalation trial as a monotherapy and in combination with targeted therapies.

  • Revenue in USD (TTM)104.03m
  • Net income in USD-216.88m
  • Incorporated2007
  • Employees192.00
  • Location
    Kura Oncology Inc4930 DIRECTORS PLACE, SUITE 500SAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 500-8800
  • Fax+1 (302) 655-5049
  • Websitehttps://www.kuraoncology.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.